Company / Shareholders' Equity
AVADEL PHARMACEUTICALS PLC Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$73.8M
FY2024
5-year range
-$21.1M / $162.3M
FY2020-FY2024
Trend
-15.8%
vs FY2023
Sector context
#178 of 213
Health Care
What the data says
AVADEL PHARMACEUTICALS PLC's shareholders' equity of $74M is lower than 84% of companies in the Health Care sector (FY2024). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$29M in FY2019 to $162M in FY2020.
Based on SEC 10-K filings.
$74M in FY2024 with a 3-year CAGR of -1.9%.
Improved from -$21M to $74M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -1.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 213This company $73.8M Sector average $2.5B
▼
-97.1% below sector average
Key checks
Key Insights
- 3-year CAGR of -1.9%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 15.8% year-over-year.
- Ranks #178 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $73.8M | -15.8% |
| FY2023 | $87.7M | +514.9% |
| FY2022 | -$21.1M | -127.0% |
| FY2021 | $78.2M | -51.8% |
| FY2020 | $162.3M | +655.7% |
| FY2019 | -$29.2M | -1150.3% |
| FY2018 | $2.8M | -96.8% |
| FY2017 | $85.6M | +103.4% |
| FY2016 | $42.1M | -39.1% |
| FY2015 | $69.1M | +176.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026